ARCTURUS THERAPEUTICS HOLDINGS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 2.90% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-03-01
- ARCTURUS THERAPEUTICS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 2.90%, a 66.67% decline from fiscal 2020.
- ARCTURUS THERAPEUTICS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 8.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2021-12-31 | 2.90% 10-K · filed 2022-03-01 |
| 2020-12-31 | 8.70% 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |